Columns archive



Columns found: 15636 Show results per page:
1 2 3 4 5 6 7 8 9
  • ASX soars as Medibank's stag catches a snag

    6:08 am

    ASX soars as Medibank's stag catches a snag

    The ASX All Ords soared 1.1% today to 5380, as investors snapped up selected blue chip miners and industrials. Medibank was left in the cold, sinking 1.9% to $2.10.

  • Proteomics seeks $6M for ASX listing to fund protein analysis businesses

    1:50 am

    Proteomics seeks $6M for ASX listing to fund protein analysis businesses

    Proteomics International Laboratories has generated $7.5M in revenues since 2001 and does not intend using its resources to develop diagnostic tools or drugs, but seeks to licence the discovered IP to major pharma groups, who have the required resources for development.

  • Triton Minerals study provides low risk, high returns at Nicanda Hill

    Tue 10:30 pm

    Triton Minerals study provides low risk, high returns at Nicanda Hill

    The scoping study results for Nicanda Hill would see a payback period within less than 12 months and projected strong NPV and IRR results for developing a low cost, high quality graphite mine for arguably the largest known graphite project.

  • Imugene is undervalued v ASX, global peers in Immuno-Oncology

    Tue 9:02 pm

    Imugene is undervalued v ASX, global peers in Immuno-Oncology

    Imugene is an immuno-oncology company developing B-cell based immunotherapies. Immunotherapy has become one of the hottest and most promising areas of study for the treatment of a variety of cancerous tumours. Pfizer and Merck will JV on up to 20 preclinical immuno-oncology programs in 2015.